Log in Register
Menu

T47D-182R2 Cell Line

Invented by Dr Anne Lykkesfeldt at Danish Cancer Society

Info

Catalogue Number 151890
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line T47D
Host Human
Tissue Breast
Disease Keywords Breast cancer, fulvestrant resistant
Model Tumour line
Relevance The T47D-182R2 Cell Line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
Production Details Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant.
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions Phenol red free RPMI 1640 + 5% FCS + glutamax + 8µg Insulin/ml + 100 nM fulvestrant.
Notes Grow with 5% feal calf serum and 100 nM fulvestrant. Estrogen and progesterone receptor negative.

Passage 165 (AL3370, AL3384)
Cellosaurus ID CVCL_1D35

References: 3 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.


Add a reference

References: 3 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.


Add a reference

References: 3 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.


Add a reference


This reagent does not have any reviews at the moment.